Aravax
Biotechnology · Melbourne, Victoria, AustraliaAbout
The treatment uses highly targeted technology that can reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax’s technology is underpinned by over a decade of research led by Professor Robyn O’Hehir and her team at Alfred Health and Monash University, which has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council of Australia. Aravax developed PVX108 by carefully selecting fragments (peptides) of peanut proteins to switch off allergic reactions to peanuts. The product does not contain whole protein allergens, which are known to cause life-threatening anaphylactic reactions. PVX108 therefore has the potential to break the paradigm of allergen immunotherapy by targeting the underlying cause of disease without exposing patients to the risk of acute reactions to treatment. For more information visit: www.aravax.com.au
Company details may include data from People Data Labs, licensed CC BY 4.0.